Fresenius Medical Care AG (FMCQF) Research & Development (2009 - 2025)

Fresenius Medical Care AG (FMCQF) has reported Research & Development for 17 consecutive years, with $45.4 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Research & Development fell 15.03% year-over-year to $45.4 million; the TTM figure through Dec 2025 stood at $177.9 million (down 10.34% YoY), while the FY2025 annual figure was $183.9 million, down 5.95% from the prior year.
• Research & Development came in at $45.4 million for Q4 2025 at Fresenius Medical Care AG, up from $44.1 million in the prior quarter.
• The five-year high for Research & Development was $77.8 million in Q4 2021, with the low at $43.1 million in Q2 2025.
• Average Research & Development over 5 years is $56.4 million, with a median of $58.2 million recorded in 2021.
• Across the five-year window, Research & Development climbed 25.47% in 2021 and retreated 24.76% in 2024, its largest moves.
• Year by year, Research & Development stood at $77.8 million in 2021, then retreated by 18.68% to $63.3 million in 2022, then rose by 12.26% to $71.0 million in 2023, then fell by 24.76% to $53.4 million in 2024, then slipped by 15.03% to $45.4 million in 2025.
• According to Business Quant data, Research & Development over the past three periods registered $45.4 million, $44.1 million, and $43.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.